PPCB
Propanc Biopharma, Inc. [PPCB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PPCB Stock Summary
In the News
PPCB Financial details
Company Rating
-
Market Cap
5.59B
Income
-2.64M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
15 May 2023
P/E
-0.01
Forward P/E
-
PEG
0
P/S
-
P/B
-0.01
P/C
-
P/FCF
-25800.51
Quick Ratio
0.03
Current Ratio
0.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
-0%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-45.43%
-
-
-
-
SMA20
-45.5%
SMA50
-57.2%
SMA100
-67.08%
Inst Own
-
Inst Trans
-
ROA
-1890%
ROE
93%
ROC
0.74%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-29%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-4-0.2625
52W High
-
52W Low
-
RSI
45.02
Rel Volume
-
Avg Volume
3.36M
Volume
900
Perf Week
17.39%
Perf Month
-55%
Perf Quarter
-67.86%
Perf Half Y
-77.5%
-
-
-
-
Beta
1.16854
-
-
Volatility
0.48%, 4.14%
Prev Close
-3.57%
Price
6.75
Change
-3.57%
Company Profile
- Volume Average 3.36M
- Market Capitalization 5.59B
- Employee 1
- CEO Mr. James Nathanielsz
- Headquarters Camberwell,VIC,AU
- IPO Date 2012-11-12
-
Website
https://www.propanc.com 
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
